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Purpose: Seminal-vesicle-sparing radical-cystectomy has been r ported to improve short-
term functional-results without compromising oncological outcomes. However, there is still a 
lack of data on long-term outcomes after seminal-vesicl -sparing radical-cystectomy. The 
aim of this study was to compare oncological and functional outcomes in patients after 
seminal-vesicle-sparing vs non- seminal-vesicle-sparing radical-cystectomy. 
Material and Methods: Oncological and functional outcomes of 470 consecutive patients 
after radical-cystectomy and orthotopic ileal reservoir from 2000 to 2017 were evaluated. 
They were stratified into 6 groups according to nerve-sparing and seminal-vesicle-sparing 


















status as attempted during surgery: no-sparing at all (n=55), unilateral-nerve-sparing (n=159), 
bilateral-nerve-sparing (n=132), unilateral-seminal-vesicle-sparing and unilateral- nerve-
sparing (n=30), unilateral-seminal-vesicle-sparing a d bilateral-nerve-sparing (n=45), and 
bilateral seminal-vesicle-sparing (n=49) and used propensity modelling to adjust for 
preoperative differences.  
Results: Median follow-up among the entire cohort was 64months. Among the 6 groups, our 
analysis showed no difference in local recurrence-fre  survival (p=0.173). However, 
progression free, cancer-specific and overall survival were more favourable in patients with 
seminal-vesicle-sparing radical-cystectomy (p<0.001, p=0.006 and p<0.001, respectively). 
Proportions of patients with erectile function recovery were higher in the seminal-vesicle-
sparing groups at all time points in all analyses, r pectively, with pronounced earlier 
recovery in patients with bilateral-SVS. Importantly, patients with seminal-vesicle-sparing 
were significantly less in need of erectile aids to achieve erection and intercourse. Over the 
whole period, daytime urinary-continence was signifcantly better in the seminal-vesicle-
sparing groups (OR 2.64 to 5.21).  
Conclusions: In a highly selected group of patients, seminal-vesicl -sparing radical-
cystectomy is oncologically safe and results in excellent functional outcomes that are reached 


























After RC, depending on the pT, 40-80% of patients are long-term-survivors, among these 
some with pelvic-node-involvement. Consequently, postoperative morbidity of RC, such as 
UI after OBS and ED which have a major-effect on QoL, should be kept as low as possible1, 
2. Several attempts at SPC have been reported to impr ve UI and ED after RC and OBS 2-11. 
These approaches aim to minimize damage to the pelvic-plexus, NVBs, and the external 
urinary-sphincter during surgery 12. Because of the high prevalence of occult-malignancy i  
the prostate and the possibility of UCa in prostatic-ducts13, we never advocated prostate-
sparing-RC, but in well-selected cases we practiced uni-or bilateral-SVS-RC in order to 
minimize possible damage to the pelvic-plexus adjacent to the SV and in the vesicoprostatic-
angle12. 
A systematic-review by Hernández et al14 reported recently that prostate-, capsule-, 
seminal-vesicle, and nerve-sparing-cystectomy is associated with more favorable functional-
outcomes compared with standard-RC without compromising oncological-outcomes. For 
analysis of both functional and oncological-outcomes, the studies only included patients with 
short-to mid-term follow-up, and the quality of the evidence was low-to-moderate. Hence, 
numerous uncertainties remain14.  
Aim of this study was to analyse long-term-UC and EFR of patients after RC combined 























2. Materials and Methods 
In this long-term-single-centre cohort-study, we reviewed data of 486 consecutive 
male patients who underwent RC and OBS at our institution from 2000 to 2017. Ethics-
approval has been obtained (KEK-Be 2016-00660). 
2.1. Patient selection 
To achieve the best possible local tumour-control, patients with BC considered for 
SVS-RC were selected restrictively2. A rigid-urethrocystoscopy with paracollicular-
biopsies and bimanual-palpation was performed in all patients before the decision for 
SVS was made. For inclusion-and exclusion-criteria for SVS-RC see Table1a. The 
anatomo-pathological basis for these exclusion-criteria is that BC located at or distal to 
the trigone represents a high-risk factor for prostatic-UCa which requires adherence to 
principles of oncosurgical-radicality in order not t  compromise oncological-outcomes. 
Similarly, in case of ipisilateral dorsal, lateral or posterior bladder-wall maximum margin 
to the tumour should be achieved. Hence, the SV should be removed in those cases. 
Patients with non-organ-confined tumour were not considered to be eligible for SVS8, 15. 
2.2. Staging, follow-up data collection 
All patients had preoperative staging and were followed prospectively according to the 
institutional follow-up-protocol published earlier16-21; In this process, the early and ongoing 
involvement of urologists as well as providing different sources of information to patients as 
well as to apprehend patient-reported outcomes is crucial22, 23.  
 
2.3. Surgical procedure 
The surgical-technique for NS-RC, PLND and OBS has been described previously2, 3, 24. 


















In brief, first, the NVB were cleaved away from the prostatic-capsule and detached. Second, 
the SV(s) were identified after a sharp transverse incision of the peritoneum was made over 
the vas deferens and SV. A plane of dissection was developed bluntly between the SV(s) and 
the dorsal bladder-wall. The dorsomedial bladder-pedicl  was transsected close to the 
bladder-wall at the level of the SVs, thus away from the pelvic-plexus, which is located 
lateral and dorsal to the SV. Dissection then proceeded caudally very close to the 
vesicoprostatic angle to avoid damage to the paraprostatic-NVB. Next a lateral incision of the 
prostatic-capsule ventral to the NVB was made running from base-to-apex. Then, the urethra 
was transected sharply at the level of the distal verumontanum. Frozen-sections were not 
routinely taken during the en-bloc-resection.  
 
2.4. Functional outcomes 
Assessment of functional-results were described in detail previously3, 16, 25. In brief, UC 
and EFR were assessed preoperatively and at each follow-up-visit using previously published 
standardized-questionnaires17 and since 2004 with the ICIQ-UI-SF and IIEF-15-
questionnaires26-28.  
Patients were classified as continent if they required ≤1 pad for safety reasons during the 
day or at night. Intact erectile-function preoperatively and EFR was defined as the ability to 
achieve an erection sufficient for penetration and maintenance of intercourse with or without 
medical-aids16. 
 
2.5. Statistical analyses 
We conducted five separate propensity analyses, 1) no-SVS versus SVS, 2) bilateral-SVS 
versus bilateral-NS, 3) unilateral-SVS versus unilateral-NS, 4) no-NS versus any-SVS and 5) 


















no-SVS versus SVS including only patients with erectil -function at time of surgery. 
Analyses 1) to 3) cover the surgical options, 4) and 5) are sensitivity-analysis. In each 
analysis, we used IPTW to construct balanced treatmnt groups with respect to risk of 
function loss and baseline-characteristics (see Supplemental-material).  
Patients with benign conditions have not been included in the analysis of oncological-
outcomes. Additionally, we excluded patients with benign conditions (n=10) as a further 
sensitivity analysis in order to derive the impact of SVS on bladder cancer patients only. 
We investigated the treatment-impact on oncological-endpoints calculating HR with 95%CI 
after IPTW. KM-curves for all six treatment groups were plotted crudely (before IPTW) with 
p-values from log-rank-tests. Statistical analyses w re performed using Stata16 (StataCorp, 
College Station, Texas, USA). For further details of the statistical methods see supplemental 
material (Supplemental-material).  
 
3. Results 
Mean age at surgery of the entire cohort was 63.7 (SD 8.9) years, and median follow-up 
was 5.3 (IQR 1.9-10.0) years (Table 1b). Of the 486patients, 16(3%) were excluded from 
analyses due to previous or early postoperative radiotherapy within 90days and 470 were 
included.  
3.1. Propensity score matching 
Propensity scores showed good overlap in all treatmn -group comparisons before and 
after IPTW (Figure1a-c), standardized differences of pre-operative variables were below 
0.1, except tumour stage and lymph node metastasis in the comparison of bilateral-NS 
versus bilateral-SVS, which was 0.165 and 0.115, respectively, indicating no meaningful 
differences between treatment-groups (Figure1d-e and Suppl.Table1a-c). As shown in 


















Suppl.Table1d, standardized-differences between patients without any-NS or SVS and 
patients with SVS (sensitivity-analysis 1) remained large also after IPTW, so results 
might still be confounded, whereas standardized-differences between patients with and 
without SVS with intact erectile-function preoperatively (sensitivity-analysis 2) all 
dropped ≤0.06, see Suppl.Table1e. 
 
    3.2. Oncological outcomes 
   3.2.1. PSM and local recurrence 
A PSM was seen in six patients of the study-cohort (1.3%). There was no significant 
difference in PSM of BC among the six groups (p=0.71). Furthermore, our un-adjusted 
analysis showed no difference in local-recurrence-fre  survival among the 6 groups 
(p=0.173). 
Urethral-recurrence occurred in 5% (24/470) patients after a median-time of 1year (IQR 
0.6-2). Four patients (1%) had a local-recurrence oth r than urethral (median 0.5 years, 
IQR 0.4-1.7).  
 
      3.2.2. Upper tract recurrence and distant metastasis 
Upper tract recurrence was observed in 4%(18/470) patients, after a median-time of 
2.1years(1.0-7.4). Twenty-six percent of patients(122/470) had distant metastasis after a 























       3.2.3. Kaplan-Meier curves 
Figure2 shows follow-up with respect to all oncological outcomes as crude Kaplan-Meier 
curves up to 10years after surgery. PFS, CSS and OS and were more favorable in patients 
with SVS-RC (p<0.001, p=0.006 and p<0.001, respectiv ly). Highest mortality was seen 
in patients without SVS or NS-RC (Table2a-b). HR after IPTW were below one for all 
outcomes in SVS vs no-SVS except CSS, indicating a reduced risk of the outcome after 
SVS. Uni- and bilateral comparisons did not show any ssociation, except for PFS after 
unilateral SVS (Table2c). Incidental prostate-cancer was found in 34% with SVS and in 
43% without SVS. PSM-rate of the prostate-cancer was 7% and 5% with and without 
SVS, respectively. Incidental prostate-cancer at RC was not associated with inferior OS, 
HR (95%CI), 1.18 (0.87-1.59).  
 
3.3. Functional outcomes 
3.3.1. Erectile function recovery 
Our primary functional-outcome was EFR in the time period from 3months to five years 
after surgery. After IPTW, proportions of patients with EFR were higher in the SVS-
groups at all time points in all analyses, respectiv ly, with pronounced earlier recovery in 
patients with bilateral-SVS (Figure 3A-C, SupplementalTable 2). Accumulated for the 
whole period this corresponds to a higher proportion of patients with EFR, OR 12.3 
(95%CI 5.74 to 26.2, p<0.001) for SVS versus no-SVS, 16.8 (3.28 to 85.6, p=0.001) for 
bilateral-SVS vs bilateral-NS and 8.60 (3.68 to 20.1, p<0.001) for unilateral-SVS vs 
unilateral-NS. Importantly, patients with SVS were significantly less in need of erectile-
aid (PDE-5-inhibitors, Alprostadil by use of MUSE or autoinjection therapy) to achieve 
erection and intercourse, respectively (Table3a). 


















Erections sufficient for intercourse were more frequ nt in the SVS-groups (see 
SupplementalTable 3 for every time point) with an overall-OR of 6.75 to 9.78 indicating 
that less invasive support was needed to achieve the ability of intercourse after SVS-vs 
no-SVS. 
Tables 3b) and 3c) show the results of our sensitivity-analyses. When comparison was 
restricted to no-NS versus any-SVS, treatment effects became very large, but may be 
influenced by residual confounding due to imbalance among treatment-groups. The 
analysis which focused on patients with erectile-function at time of surgery yielded a 
functional benefit of SVS in every respect. The odds of EFR is 10times higher after SVS 
in this patient-group. 
 
3.3.2. Urinary continence 
Daytime-UC was in general high from 6months postoperatively onwards with slightly 
higher proportions in patients after SVS at every single time-point, except for bilateral-
NS vs bilateral-SVS, where proportions were basically the same from one year on. Over 
the whole period, daytime-UC was significantly better in the SVS-groups (OR 2.64 to 
5.21). With respect to nighttime-UC, found higher proportions after SVS in all 
comparisons, which did not reach statistical-signifcance for unilateral-NS vs unilateral-
SVS (Figure 4A-C, and SupplementalTable 4). 
3.3.3. Residual urine 
SVS decreased the proportion of patients with residual-urine ≥50ml, yielding ORs 
markedly below one, however not reaching statistical significance for bilateral-SVS vs 
bilateral-NS (Figure3d-e and Table3). 


















3.3.4. Sensitivity analysis for bladder cancer patients only 
After excluding patients with benign disease, propensity modelling worked equally 
well, and the OR of SVS showed similar patterns for functional outcomes, except that 
nighttime continence did not reach statistical signif cance, see Supplemental Table 5, and 
Supplemental Figures 1 and 2. 
 
4. Discussion 
Our analysis yielded several important findings. Most importantly, oncological-outcomes 
were not inferior in all degrees of SVS. Second, we found an earlier recovery of UC in 
patients with SVS compared to NS only. Likewise, SVS has a beneficial impact on early-EFR 
which remains significantly better over a longer peiod of time. Having conducted a 
propensity-score-weighting, the estimation of the eff ct of SVS on functional and-
oncological outcomes is even more valid.  
Our rate of local recurrence other than urethral of 6% in patients after SVS-RC is in line 
with the data of Hernandez et al which reported rates fter SPC between 2.2-16.1%14. In 
patients with SVS-RC reported 5-or 6y-CSS-and OS-rates range from 35-93% and 47-93%, 
respectively.4-6, 8, 11. Our 5-and 10y-CSS and OS in patients with SVS was similar with 87% 
and 81%,and 80% and 71%, respectively. 
In our series, local recurrence-free-survival was similar among all groups, PFS, CSS and 
OS were more favorable for the SVS-group. This is, propensity-weighting notwithstanding, 
clearly owing to a very careful patient-selection with a remaining bias. Patients have to fulfill 
certain inclusion-criteria to be considered for SVS. Therefore, a general applicability of these 
findings to all patients undergoing RC for BC is not p ssible. Hence, we believe that this 


















technique, a careful patient selection provided, constitutes no compromise of oncological-
principles, even in the case of unexpected limited invasion of the UCa into the prostate.  
Hernandez et al reported day-and nighttime-continence from 88.9-100% and 55-88.9%, 
respectively14. However, with the exception of two comparative-studies of Basiri et al and 
Mertens et al5, 29 no difference in favor of the sexual-preserving-technique was observed in 
other studies. However, we could show that UC-recovry was significantly better in the SVS-
groups during daytime (OR 2.64 to 5.21) and, less pronounced, during nighttime (OR 1.08 to 
4.37) in any of our comparisons. This might be because the hypogastric nerve fibres which 
run along the tip of the SV can be spared more extensiv ly with the SVS-approach as 
compared to the NS-approach3, 30. Therefore, in order to optimize urinary-continenc, we are 
always aiming at sparing the SV if it’s safe from an oncological standpoint. Hence, this is the 
reason why we perform SVS in some patients even with decreased erectile function 
preoperatively. Hence, although baseline sexual functio  clearly plays an important role in 
the decision whether SVS should be aimed at, it is not the only variable we take into account. 
 
From a neuroanatomical point of view, the earlier recovery in daytime-continence may be 
explained with lesser extent of neurapraxia which normally resolves within 24months 
postoperatively. The better UC-rates over time thoug  is likely due to less harm to the nerves 
surrounding the tips of the SVs12. This is substantiated by the studies by Roethlisberger et al 
who could demonstrate in their anatomical study on embalmed hemipelves that the 
innervation of the urethra and the corpora cavernosa derives from two origins. Not only from 
the inferior part of the pelvic-plexus which runs towards the apex of the prostate and the 
rhabdosphincter, but also a more superior-part from a sub-plexus around the SVs which 
innervates the more proximal prostate and the prostatic-urethra with the lissosphincter. 


















Furthermore, a connection between the two parts was demonstrated in approximately one 
third of the samples investigated. This could explain the significantly better recovery of 
continence after pelvic surgery30. 
In line with our data, reported EFR in the systematic review of Hernandez et al were 
significantly better compared to standard-cystectomy, ranging from 58-94% for SPC14. Our 
present study is the first which compares the different SVS-grades, but also different SVS-
grades to NS-RC and standard-RC. Many studies included were heterogenous (i.e.studies 
included laparaoscopic and robotic-surgery and heterotopic urinary diversion) and did not 
compare different sexual-sparing-techniques to standard-cystectomy at all. In our cohort, 
after IPTW, this comparison showed likewise significantly better functional-outcomes in 
favor of patients with SVS (see SupplementalTables2-4). We also tried to construct 
comparable groups of patients without any NS or SVS and patients with SVS using 
propensity-modelling, but baseline-characteristics between the two subcohorts differed 
substantially even after IPTW (standardized-differences >0.1). Therefore, results of 
comparison of these treatment-groups have to be interpreted with caution, as residual-
confounding is likely. Importantly, all patients with SVS underwent also NS as technically, 
the SV cannot be spared without sparing the nerves. H nce, for reasons of surgical feasibility, 
the true effect of SVS is entangled with the effect of NS. 
Furthermore, follow-up for EFR and UC was only 6 to 12months in most of the studies, 
whereas our median follow-up was 64months. This is of paramount importance to assess the 
impact of SPC, as we could demonstrate that patients suffering from UI and ED may regain 
function even after 12months whereby the beneficial mpact of SPC on UI and ED becomes 
even more apparent over time. This may be due to the ngoing resolution of neurapraxia seen 
up to 2years after major pelvic surgery 3, 16.  


















The main limitation of the present study is lack of randomisation of BC-patients 
undergoing SVS vs non-SVS resulting in a certain selection-bias with poorer survival-data in 
the non-SVS-group, owing to more advanced-disease. However, we overcame this limitation 
at least partially with propensity score-weighted-analysis. Furthermore, those encouraging 
survival-data attest the careful selection of patients undergoing SVS-RC which is of utmost 
importance to achieve good oncological and functional-outcomes. Whether a preoperative-
MRI might optimize patient-selection is under current investigation.  
 
5. Conclusion 
In a highly-selected group of patients, SVS-RC is oncologically safe and results in 
excellent functional-outcomes that are achieved at an earlier timepoint postoperatively and 
remain superior over a longer time-period. 
 
Abbreviations and Acronyms 
RC = radical cystoprostatectomy 
pT = pathological tumour stage 
UI = urinary incontinence 
OBS = orthotopic bladder substitution 
ED = erectile dysfunction 
QoL = quality of life 
SPC = sexual-preserving cystectomy 
UCa = urothelial cancer 
NVB = neurovascular bundle 


















SV(s) = seminal vesicle(s) 
SVS-RC = seminal vesicle-sparing cystectomy 
EFR = erectile function recovery 
UC = urinary continence 
BC = bladder cancer 
CT = computed tomography 
MRI = magnetic resonance imaging 
NS = nerve sparing 
PLND = pelvic lymph node dissection 
ICIQ-UI-SF = International Consultation on Incontinence Questionnaire Urinary 
Incontinence Short Form 
IIEF = International Index of Erectile Function 
IPTW = inverse probability of treatment weighing 
HR = hazard ratio 
CI = confidence interval 
IQR = interquartile range 
PSM = positive surgical margin 
PFS = progression free-survival 
CSS = cancer-specific survival 
OS = overall survival 
HR = hazard ratio 
OR = odds ratio 
PDE-5 = Phosphodiesterase-5 


















MUSE = Medicated Urethral System for Erection 
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Table 1a: Inclusion and exclusion criteria for seminal vesicle sparing radical cystectomy 
Exclusion criteria for any SVS Inclusion criteria for unilateral SVS Inclusion criteria for bilateral SVS 
Location of tumour at trigonal area 
and bladder neck 
Tumour only in contralateral dorsal, 
lateral or posterior bladder wall 
Bladder dome and anterior bladder 
wall tumours only 
 
Invasive tumour in prostatic urethra 
(paracollicular area) 
 Benign conditions (e.g. low-





SVS, seminal vesicle sparing 
















 Table 1b: Baseline characteristics of 470 patients with bladder cancer undergoing radical cystectomy 
 
NS, nerve sparing; SVS, seminal vesicle sparing; BMI, body mass index; CACI, Charlson-Age Comorbidity Index; COPD, chronic obstructive 
pulmonary disease; TUR-B, transurethral resection of the bladder; CIS, carcinoma in situ; PSM, positive surgical margin 













Number of patients 55 159 132 30 45 49  
 
Preoperative 
       
Age [years], mean (SD) 65 (9.2) 64 (8.7) 64 (7.6) 62 (8.8) 62 (8.8) 61 (12) 0.21 
BMI [kg/m2], mean (SD) 27 (4.1) 27 (5.1) 27 (3.9) 26 (3.3) 27 (4.4) 27 (4.5) 0.81 
CACI ≥ 3, n (%) 5 (9.1) 36 (23) 28 (21) 5 (17) 4 (8.9) 14 (29) 0.045 
Hypertension, n (%) 28 (51) 77 (48) 57 (43) 17 (57) 17 (38) 23 (47) 0.57 
Coronary artery disease, n (%) 13 (24) 37 (23) 24 (18) 7 (23) 6 (13) 11 (22) 0.67 
Hypercholesterinemia, n (%)  9 (16) 36 (23) 28 (21) 11 (37) 7 (16) 18 (37) 0.05 
Diabetes, n (%) 13 (24) 15 (9.4) 14 (11) 4 (13) 4 (8.9) 5 (10) 0.16 
COPD, n (%) 6 (11) 31 (19) 22 (17) 8 (27) 8 (18) 9 (18) 0.56 
Nicotine, n (%) 35 (64) 106 (67) 88 (67) 21 (70) 21 (47) 29 (59) 0.19 
Multiple TUR-B, n (%) 17 (31) 35 (22) 42 (32) 5 (17) 10 (22) 20 (41) 0.06 
Pathological tumor stage [TUR-B], n (%)       <0.001 
      ≤pTa 1 (1.8) 2 (1.3) 12 (9.1) 0 (0) 1 (2.2) 11 (22)  
      pT1 16 (29) 24 (15) 34 (26) 7 (23) 11 (24) 17 (35)  
      pT2 38 (69) 133 (84) 86 (65) 23 (77) 33 (73) 21 (43)  
Carcinoma in situ [TUR-B], n (%) 16 (29) 45 (28) 48 (36) 7 (23) 13 (29) 16 (33) 0.66 
Histological variants [TUR-B], n (%)       0.87 
     squamous differentiation 1 (1.8) 5 (3.1) 1 (0.76) 1 (3.3) 3 (6.7) 1 (2.0)  
     small cell/neuroendocrine different. 0 (0) 3 (1.9) 1 (0.76) 0 (0) 2 (4.4) 0 (0)  
     sarcomatoide differentiation 0 (0) 3 (1.9) 3 (2.3) 0 (0) 2 (4.4) 1 (2.0)  
     other variants 0 (0) 2 (1.3) 3 (2.3) 0 (0) 0 (0) 0 (0)  
Lymphovascular invasion, n (%) 3 (5.5) 23 (14) 13 (10) 3 (10) 7 (16) 5 (10) 0.48 
Hydronephrosis, n (%) 10 (18) 35 (22) 24 (18) 3 (10) 3 (6.7) 9 (18) 0.21 
Intravesical instillation, n (%) 13 (24) 27 (17) 35 (27) 1 (3.3) 12 (27) 21 (43) <0.001 
Neoadjuvant chemotherapy, n (%) 5 (9.1) 34 (21) 21 (16) 2 (6.7) 9 (20) 4 (8.2) 0.08 
Adjuvant/palliative chemotherapy, n (%) 21 (38) 50 (31) 31 (23) 8 (27) 6 (13) 7 (14) 0.013 
Paracollicular biopsy, n (%)       0.73 
    negative 50 (91) 153 (96) 121 (92) 30 (100) 44 (98) 48 (98)  
    CIS 3 (5.5) 3 (1.9) 7 (5.3) 0 (0) 1 (2.2) 0 (0)  
    pTa G1-2 1 (1.8) 0 (0) 1 (0.76) 0 (0) 0 (0) 0 (0)  
    pTa G3 0 (0) 2 (1.3) 1 (0.76) 0 (0) 0 (0) 0 (0)  
    ≥ T1 1 (1.8) 1 (0.63) 2 (1.5) 0 (0) 0 (0) 1 (2.0)  




       
Tumor pathology, n (%)       <0.001 
    pT0 0 (0) 9 (5.7) 22 (17) 1 (3.3) 9 (20) 10 (20)  
    pT1 14 (25) 24 (15) 39 (30) 8 (27) 12 (27) 19 (39)  
    pT2 17 (31) 59 (37) 44 (33) 15 (50) 14 (31) 9 (18)  
    pT3 16 (29) 59 (37) 25 (19) 5 (17) 10 (22) 10 (20)  
    pT4 8 (15) 8 (5.0) 2 (1.5) 1 (3.3) 0 (0.0) 1 (2.0)  
Lymph node metastasis [pN+], n (%) 19 (35) 48 (30) 18 (14) 9 (30) 4 (8.9) 3 (6.1) <0.001 
Number of lymph nodes removed 29 (9.1) 34 (14) 38 (17) 37 (23) 39 (13) 29 (16) <0.001 
CIS pathology, n (%) 22 (40) 67 (42) 61 (46) 10 (33) 27 (60) 23 (47) 0.23 
High grade [G3], n (%) 55 (100) 148 (93) 108 (82) 25 (83) 39 (87) 36 (73) <0.001 
PSM bladder cancer, n (%) 1 (1.8) 1 (0.63) 2 (1.5) 0 (0) 1 (2.2) 1 (2.0) 0.71 
incidental prostate cancer, n (%) 20 (36) 69 (43) 59 (45) 14 (47) 16 (36) 15 (31) 0.69 
PSM prostate cancer, n (%) 2 (10) 4 (6) 1 (2) 2 (14) 1 (6) 0 (0) 0.33 
















Table 2: Occurrence of recurrence and survival data of 470 patients undergoing radical cystectomy and orthotopic bladder 
substitution 
Table 2a: Number of local and distant 





*Local recurrence was defined as recurrence in the pelvic soft tissue or pelvic lymph nodes detected with imaging studies. Involvement of lymph 
nodes above the level of the iliac bifurcation and visceral metastasis was classified as distant metastasis. 
 
Table 2b: Survival data after inverse probability of treatment weighing  
        
        
Table 2c: Safety analysis: impact of SVS on tumor recurrence and death - inverse probability of treatment-weighted hazard ratios of 
SVS on time-to-event oncological outcomes 
 No SVS vs SVS Bilateral NS vs bilateral SVS Unilateral NS vs unilateral SVS 
 HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Local recurrence-free survival 0.16 (0.04 to 0.66) 0.012 0.18 (0.02 to 1.42) 0.105 0.19 (0.02 to 1.60) 0.128 
Progression-free survival 0.59 (0.38 to 0.91) 0.018 0.94 (0.47 to 1.88) 0.860 0.53 (0.29 to 0.99) 0.047 
Cancer-specific survival 0.65 (0.36 to 1.19) 0.165 1.02 (0.37 to 2.83) 0.966 0.59 (0.26 to 1.35) 0.214 
Overall survival 0.59 (0.36 to 0.96) 0.035 1.12 (0.54 to 2.33) 0.769 0.49 (0.23 to 1.01) 0.054 
SVS, seminal vesicle sparing; NS, nerve sparing; HR, hazard ratio; CI, confidence interval 
Localization n (%) median (IQR) 
Urethral recurrence 24 (5) 1.0 (0.6 – 2.0) 
Recurrence upper urinary tract 18 (4) 2.1 (1.0 – 7.4) 
Local recurrence other than urethral* 28 (6) 1.1 (0.5 – 2.1) 
Distant metastasis* 122 (26) 1.0 (0.5 – 2.0) 
 1 year 2 years 5 years 10 years 
 all no SVS SVS all 
no 
SVS SVS all 
no 
SVS SVS all 
no 
SVS SVS 
Local recurrence-free survival (%) 98 97 100 97 95 100 96 93 99 95 92 99 
Progression-free survival (%) 81 79 83 75 70 82 67 59 75 57 51 65 
Cancer-specific survival (%) 95 93 96 87 86 89 79 75 84 74 69 79 
Overall survival (%) 92 89 95 84 80 88 72 67 78 62 56 69 
















Table 3: Erectile function and urinary continence 3 months to 5 years after surgery of SVS as compared to no SVS 
Table 3a: IPT-weighted odds ratio of preserved erectile function 3 months to 5 years after surgery of SVS as compared to no SVS 
 No SVS vs SVS Bilateral NS vs bilateral SVS Unilateral NS vs unilateral SVS 
 OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
EFR 12.3 (5.74 to 26.2) <0.001 16.8 (3.28 to 85.6) 0.001 8.60 (3.68 to 20.1) <0.001 
Erection* 1.75 (1.17 to 2.64) 0.007 1.21 (0.63 to 2.31) 0.564 1.98 (1.14 to 3.46) 0.016 
Aid**(ordinal) 9.27 (4.64 to 18.5) <0.001 9.78 (2.73 to 35.1) <0.001 6.75 (2.98 to 15.3) <0.001 
Daytime continence 4.65 (2.75 to 7.88) <0.001 2.64 (1.14 to 6.12) 0.023 5.21 (2.45 to 11.1) <0.001 
Nighttime continence 1.94 (1.07 to 3.52) 0.028 4.37 (1.67 to 11.4) 0.003 1.08 (0.48 to 2.41) 0.852 
Residual urine ≥ 50ml 0.29 (0.15 to 0.56) <0.001 0.57 (0.23 to 1.42) 0.225 0.25 (0.09 to 0.66) 0.005 
 
Table 3b: Sensitivity analysis 1  
IPT-weighted odds ratio of preserved organ function 3 months to 5 years after SVS surgery (n=124) as compared to no SVS (n=55) 
in patients with standard radical cystectomy vs. any SVS. 
 
 SVS vs no SVS 
 OR (95% CI) P value 
EFR 155 (32.96 to 733) <0.001 
Erection* 2.81 (1.07 to 7.36) 0.036 
Aid**(ordinal) 78.7 (24.8 to 250) <0.001 
Daytime continence 5.19 (2.04 to 13.2) 0.001 
Nighttime continence 6.20 (2.09 to 18.4) 0.001 
Residual urine ≥ 50ml 0.18 (0.08 to 0.43) <0.001 
 
Table 3c: Sensitivity analysis 2  
IPT-weighted odds ratio of preserved organ function 3 months to 5 years after surgery of SVS (n=108) as compared to no SVS (n=257) in patients 
with preserved erectile function pre-operatively. 
 SVS vs no SVS 
 OR (95% CI) P value 
EFR 10.5 (4.97 to 22.3) <0.001 
Erection* 1.68 (1.11 to 2.54) 0.014 
Aid**(ordinal) 8.51 (4.17 to 17.4) <0.001 
Daytime continence 2.73 (1.56 to 4.77) <0.001 
Nighttime continence 1.66 (0.90 to 3.08) 0.106 
Residual urine ≥ 50ml 0.30 (0.14 to 0.67) 0.003 
 
SVS, seminal vesicle sparing; EFR, erectile function recovery; UC, urinary continence; OR, odds ratio; CI, confidence interval. 
*Iterations did not converge, so the estimate is based on a generalized estimating equation-model. 
**“Aid” denotes the amount of support needed for sexual intercourse, the OR expresses how likely it is that a patient after SVS need less support 
as compared to a patient after no-SVS. 
Remark: p values related to continence during day were relatively low because proportions of continent patients were close to 100% for most time 
points, so confidence intervals of the proportions are small. Hence, differences between treatment groups appeared more significant as compared 
to continence during night for each time point (see Figure 4 and Supplemental table 4) and especially for the entire period, as low variability leads 
to higher precision. 
 
 
















Figure 1: Propensity models 






































































































Figure 3: postoperative rates of erectile function recovery and erection not sufficient for intercourse  i r  : t r ti  r t  f r til  f ti  r r   r ti  t ffi i t f r i t r r   
 

















Figure 4: postoperative rates of day and nighttime continence, and residual urine  
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